|Videos|January 21, 2022
The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the discussion, Lepor explained inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Finerenone for Chronic Kidney Disease in Adults With Type 1 Diabetes
2
Hepatitis B Is Still Active: What Pharmacists Need to Know About Adult Transmission Rates and Vaccine Gaps
3
Expanding the Field: Who Now Qualifies for CGM, AID, and Continuous Ketone Monitoring?
4
Depression Common in Asthma, But Moderate to Severe Disease Worsens Outcomes
5